壽康集團(00575.HK)附屬「深度青春」新聘行政總裁
壽康集團(00575.HK)公布,Deep Longevity正通過建立團隊、產品、技術及商業模式的多項舉措繼續增長。Deep Longevity附屬「深度青春」新聘一位行政總裁Deepankar Nayak。
Deep Longevity使用公司人工智能主導的深度學習模型構建及商業化各種老化時鐘,由於正尋求發掘虛擬心理健康市場上的需求,故特別關注MindAge產品。
公司正考慮創建針對美國、英國及歐洲的大、中型僱主的企業級MindAge產品,其將成為僱員在工作場所管理其虛擬心理健康的首選平台,安全、可靠、私密且個性化。此將成為2022年餘下時間及邁進2023年的重點專注產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.